2 results
Approved WMOCompleted
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.
Approved WMOCompleted
The primary objectives are to establish dose-response relationship for 2% transdermal testosterone (Tostran®) gel to achieve total testosterone serum concentrations between 1.5-2.5 nmol/l in transgender women after vaginoplasty and to assess side…